FDA Reconsiders Curbs on Avandia

The Wall Street Journal (online registration required): Food and Drug Administration documents released Monday suggested the agency was considering reviving a drug that has been highly restricted for nearly three years—the GlaxoSmithKline GSK.LN +0.03% PLC diabetes pill Avandia—and restoring it to full marketing status in the U.S.

Read article